David Chang Biography and Net Worth

President, Chief Executive Officer and Co-Founder of Allogene Therapeutics

David Chang, M.D., Ph.D, is the President, Chief Executive Officer and Co-Founder of Allogene Therapeutics. He previously served as Executive Vice President, Research & Development and Chief Medical Officer of Kite, a Gilead Company. He has an industry-leading track record of innovation in the field of oncology drug development, including the development of Yescarta® (axicabtagene ciloleucel), the first CAR T therapy approved for non-Hodgkin lymphoma, Blincyto® (blinatumomab), a bispecific T cell engager antibody in acute lymphocytic leukemia, IMLYGIC® (talimogene laherparepvec), a first-of-its-kind oncolytic immunotherapy in melanoma, among others. From 2002 to 2014, he held senior leadership roles at Amgen. Prior to that, Dr. Chang held a faculty appointment in the Department of Medicine and Microbiology, Immunology & Molecular Genetics at the David Geffen School of Medicine at the University of California, Los Angeles. He obtained a B.S. in biology from the Massachusetts Institute of Technology (MIT) and an M.D. and Ph.D. from Stanford University. Dr. Chang completed postdoctoral fellowship at MIT and postgraduate clinical training at Brigham and Women’s Hospital and Dana-Farber Cancer Institute at Harvard Medical School.

What is David D. Chang's net worth?: The estimated net worth of David D. Chang is at least $7.60 million as of March 14th, 2025. Dr. Chang owns 5,276,569 shares of Allogene Therapeutics stock worth more than $7,598,259 as of December 5th. This net worth evaluation does not reflect any other investments that Dr. Chang may own. Additionally, Dr. Chang receives an annual salary of $994,600.00 as President, Chief Executive Officer and Co-Founder at Allogene Therapeutics. Learn More about David D. Chang's net worth.
How old is David D. Chang?: Dr. Chang is currently 64 years old. There are 8 older executives and no younger executives at Allogene Therapeutics. Learn More on David D. Chang's age.
What is David D. Chang's salary?: As the President, Chief Executive Officer and Co-Founder of Allogene Therapeutics, Inc., Dr. Chang earns $994,600.00 per year. Learn More on David D. Chang's salary.
How do I contact David D. Chang?: The corporate mailing address for Dr. Chang and other Allogene Therapeutics executives is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. Allogene Therapeutics can also be reached via phone at (650) 457-2700 and via email at [email protected]. Learn More on David D. Chang's contact information.
Has David D. Chang been buying or selling shares of Allogene Therapeutics?: David D. Chang has not been actively trading shares of Allogene Therapeutics during the past quarter. Most recently, David D. Chang sold 46,668 shares of the business's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $1.96, for a transaction totalling $91,469.28. Following the completion of the sale, the chief executive officer now directly owns 5,276,569 shares of the company's stock, valued at $10,342,075.24. Learn More on David D. Chang's trading history.
Who are Allogene Therapeutics' active insiders?: Allogene Therapeutics' insider roster includes Rafael Amado (CMO), Arie Belldegrun (Director), Veer Bhavnagri (General Counsel), David Chang (President, Chief Executive Officer and Co-Founder), Earl Douglas (SVP), Franz Humer (Director), Stephen Mayo (Director), Geoffrey Parker (Executive Vice President, Chief Financial Officer), Zachary Roberts (Executive Vice President, Research & Development, Chief Medical Officer), Owen Witte (Director), and Annie Yoshiyama (SVP). Learn More on Allogene Therapeutics' active insiders.
Are insiders buying or selling shares of Allogene Therapeutics?: During the last year, insiders at the sold shares 10 times. They sold a total of 169,568 shares worth more than $294,129.46. The most recent insider tranaction occured on October, 21st when CFO Geoffrey M Parker sold 36,744 shares worth more than $46,297.44. Insiders at Allogene Therapeutics own 13.2% of the company. Learn More about insider trades at Allogene Therapeutics.
Information on this page was last updated on 10/21/2025.

David D. Chang Insider Trading History at Allogene Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/14/2025	Sell	46,668	$1.96	$91,469.28	5,276,569
3/15/2022	Sell	23,648	$7.65	$180,907.20
3/16/2020	Sell	20,335	$19.31	$392,668.85	2,215,426
10/15/2018	Buy	40,000	$18.00	$720,000.00

David D. Chang Buying and Selling Activity at Allogene Therapeutics

Allogene Therapeutics Company Overview

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Today's Range

Now: $1.44

$1.41

$1.51

50 Day Range

MA: $1.28

$1.05

$1.52

2 Week Range

Now: $1.44

$0.86

$3.78

Volume

1,536,230 shs

Average Volume

2,359,507 shs

Market Capitalization

$323.61 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.47

David Chang Biography and Net Worth

What is David D. Chang's net worth?

How old is David D. Chang?

What is David D. Chang's salary?

How do I contact David D. Chang?

Has David D. Chang been buying or selling shares of Allogene Therapeutics?

Who are Allogene Therapeutics' active insiders?

Are insiders buying or selling shares of Allogene Therapeutics?